{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:47:01Z","timestamp":1789181221484,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is a debilitating neurodegenerative synucleinopathy, characterized by dopaminergic degeneration, pathological deposition of alpha-synuclein (\u03b1-Syn), and neuroinflammation in both motor regions of the midbrain and non-motor areas of the cortex. Despite its motor-centric characterization, visual disturbances such as hallucinations, diplopia, altered contrast sensitivity and retinal abnormalities are well-documented non-motor changes of PD. While this evidence points to neuropathological processes in PD that extend beyond the brain, the neuropathological basis of retinal dysfunction and the role of \u03b1-Syn remain poorly investigated. Given the central neuropathological role of \u03b1-Syn in the PD brain, we assessed whether the retina is affected in a translational rat model of PD based on the intranigral bilateral infusion of toxic oligomers of human \u03b1-Synuclein (H-\u03b1-SynOs). Rats were stereotaxically injected with H-\u03b1-SynOs or PBS (Vehicle) into the substantia nigra pars compacta (SNpc) and sacrificed 3 months post-infusion. Thereafter, several retinal tissue pathological parameters, along with the expression patterns of selected miRNAs and inflammatory markers, were assessed. The retina of rats infused with H-\u03b1-SynOs exhibited high levels of phosphorylated-\u03b1-Syn (p-\u03b1-Syn), along with a significant decrease of tyrosine hydroxylase (TH) expression, reflecting dopaminergic neuron disfunction. Analysis of PD-associated miRNAs in the retina also revealed heightened levels of miR-384-5p, which inversely correlated with the expression of its predicted molecular target, SIRT1, in rats infused with H-\u03b1-SynOs. Consistently, H-\u03b1-SynOs infusion induced a widespread activation of retinal astrocytes and microglial markers, associated with a heightened proinflammatory cytokine signaling downstream of TLR4\/NF\u03baB. Collectively, our data reveal that H-\u03b1-SynOs extend their neuropathological effects to retinal damage, reinforcing our rodent model ability to recapitulate PD pathology in both brain and retina. This study underscores the robustness of this preclinical model and its value as translational system for testing proactive interventions targeting PD-related pathology.<\/jats:p>","DOI":"10.1038\/s41420-025-02830-0","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:49:50Z","timestamp":1764341390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retinal alterations resemble brain pathology in a rat model of Parkinson\u2019s disease induced by intranigral infusion of \u03b1-synuclein oligomers"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5517-8223","authenticated-orcid":false,"given":"Chiara","family":"Burgaletto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Flavia","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Palmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Bianca Maria","family":"Platania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Di Benedetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bucolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5934-3962","authenticated-orcid":false,"given":"Nunzio","family":"Vicario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"De Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4765-0663","authenticated-orcid":false,"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna R.","family":"Carta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-9337","authenticated-orcid":false,"given":"Giuseppina","family":"Cantarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"2830_CR1","first-page":"1","volume":"2016","author":"L Xu","year":"2016","unstructured":"Xu L, Pu J. Alpha-synuclein in Parkinson\u2019s disease: from pathogenetic dysfunction to potential clinical application. Parkinson\u2019s Dis. 2016;2016:1\u201310.","journal-title":"Parkinson\u2019s Dis"},{"key":"2830_CR2","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. \u03b1-Synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 1998;95:6469\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2830_CR3","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00702-015-1405-5","volume":"122","author":"KA Jellinger","year":"2015","unstructured":"Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm (Vienna). 2015;122:1429\u201340.","journal-title":"J Neural Transm (Vienna)"},{"key":"2830_CR4","doi-asserted-by":"publisher","first-page":"a009282","DOI":"10.1101\/cshperspect.a009282","volume":"2","author":"P Mazzoni","year":"2012","unstructured":"Mazzoni P, Shabbott B, Cort\u00e9s JC. Motor control abnormalities in Parkinson\u2019s disease. Cold Spring Harb Perspect Med. 2012;2:a009282.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2830_CR5","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cnp.2022.06.002","volume":"7","author":"R Chen","year":"2022","unstructured":"Chen R, Berardelli A, Bhattacharya A, Bologna M, Chen K-HS, Fasano A, et al. Clinical neurophysiology of Parkinson\u2019s disease and parkinsonism. Clin Neurophysiol Pract. 2022;7:201\u201327.","journal-title":"Clin Neurophysiol Pract"},{"key":"2830_CR6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrn.2017.62","volume":"18","author":"AHV Schapira","year":"2017","unstructured":"Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017;18:435\u201350.","journal-title":"Nat Rev Neurosci"},{"key":"2830_CR7","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1136\/jnnp.2007.124677","volume":"79","author":"DR Williams","year":"2007","unstructured":"Williams DR, Warren JD, Lees AJ. Using the presence of visual hallucinations to differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol, Neurosurg Psychiatry. 2007;79:652\u20135.","journal-title":"J Neurol, Neurosurg Psychiatry"},{"key":"2830_CR8","doi-asserted-by":"publisher","first-page":"s91","DOI":"10.1007\/s100720200085","volume":"23","author":"M Onofrj","year":"2002","unstructured":"Onofrj M, Thomas A, D\u2019Andreamatteo G, Iacono D, Luciano AL, Di Rollo A, et al. Incidence of RBD and hallucination in patients affected by Parkinson\u2019s disease: 8-year follow-up. Neurol Sci. 2002;23:s91\u20134.","journal-title":"Neurol Sci"},{"key":"2830_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10072-014-1930-2","volume":"36","author":"I \u0160tenc Bradvica","year":"2015","unstructured":"\u0160tenc Bradvica I, Bradvica M, Mati\u0107 S, Reisz-Maji\u0107 P. Visual dysfunction in patients with Parkinson\u2019s disease and essential tremor. Neurol Sci. 2015;36:257\u201362.","journal-title":"Neurol Sci"},{"key":"2830_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nrneurol.2012.227","volume":"9","author":"A London","year":"2013","unstructured":"London A, Benhar I, Schwartz M. The retina as a window to the brain-from eye research to CNS disorders. Nat Rev Neurol. 2013;9:44\u201353.","journal-title":"Nat Rev Neurol"},{"key":"2830_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-023-03373-6","volume":"23","author":"R Elanwar","year":"2023","unstructured":"Elanwar R, Al Masry H, Ibrahim A, Hussein M, Ibrahim S, Masoud MM. Retinal functional and structural changes in patients with Parkinson\u2019s disease. BMC Neurol. 2023;23:330.","journal-title":"BMC Neurol"},{"key":"2830_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jns.2015.05.007","volume":"355","author":"J Chorostecki","year":"2015","unstructured":"Chorostecki J, Seraji-Bozorgzad N, Shah A, Bao F, Bao G, George E, et al. Characterization of retinal architecture in Parkinson\u2019s disease. J Neurol Sci. 2015;355:44\u20138.","journal-title":"J Neurol Sci"},{"key":"2830_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/08820538.2017.1307423","volume":"33","author":"MM Moschos","year":"2018","unstructured":"Moschos MM, Chatziralli IP. Evaluation of choroidal and retinal thickness changes in parkinson\u2019s disease using spectral domain optical coherence tomography. Semin Ophthalmol. 2018;33:494\u20137.","journal-title":"Semin Ophthalmol"},{"key":"2830_CR14","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/ana.25897","volume":"88","author":"I Ortu\u00f1o-Lizar\u00e1n","year":"2020","unstructured":"Ortu\u00f1o-Lizar\u00e1n I, S\u00e1nchez-S\u00e1ez X, Lax P, Serrano GE, Beach TG, Adler CH, et al. Dopaminergic retinal cell loss and visual dysfunction in Parkinson disease. Ann Neurol. 2020;88:893\u2013906.","journal-title":"Ann Neurol"},{"key":"2830_CR15","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/mds.27392","volume":"33","author":"I Ortu\u00f1o-Lizar\u00e1n","year":"2018","unstructured":"Ortu\u00f1o-Lizar\u00e1n I, Beach TG, Serrano GE, Walker DG, Adler CH, Cuenca N. Phosphorylated \u03b1-synuclein in the retina is a biomarker of Parkinson\u2019s disease pathology severity. Mov Disord. 2018;33:1315\u201324.","journal-title":"Mov Disord"},{"key":"2830_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/ana.24182","volume":"75","author":"I Bodis-Wollner","year":"2014","unstructured":"Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. \u03b1-synuclein in the inner retina in parkinson disease. Ann Neurol. 2014;75:964\u20136.","journal-title":"Ann Neurol"},{"key":"2830_CR17","doi-asserted-by":"publisher","first-page":"4194","DOI":"10.1073\/pnas.1100976108","volume":"108","author":"B Winner","year":"2011","unstructured":"Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci USA. 2011;108:4194\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2830_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.bbi.2018.02.012","volume":"69","author":"P La Vitola","year":"2018","unstructured":"La Vitola P, Balducci C, Cerovic M, Santamaria G, Brandi E, Grandi F, et al. Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain Behav Immun. 2018;69:591\u2013602.","journal-title":"Brain Behav Immun"},{"key":"2830_CR19","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1038\/emboj.2009.257","volume":"28","author":"DP Karpinar","year":"2009","unstructured":"Karpinar DP, Balija MBG, K\u00fcgler S, Opazo F, Rezaei-Ghaleh N, Wender N, et al. Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson\u2019s disease models. EMBO J. 2009;28:3256\u201368.","journal-title":"EMBO J"},{"key":"2830_CR20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/ijms25010360","volume":"25","author":"K Saramowicz","year":"2023","unstructured":"Saramowicz K, Siwecka N, Galita G, Kucharska-Lusina A, Rozp\u0119dek-Kami\u0144ska W, Majsterek I. Alpha-synuclein contribution to neuronal and glial damage in Parkinson\u2019s disease. Int J Mol Sci. 2023;25:360.","journal-title":"Int J Mol Sci"},{"key":"2830_CR21","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.3390\/ijms21228535","volume":"21","author":"L Boi","year":"2020","unstructured":"Boi L, Pisanu A, Palmas MF, Fusco G, Carboni E, Casu MA, et al. Modeling Parkinson\u2019s disease neuropathology and symptoms by intranigral inoculation of preformed human \u03b1-synuclein oligomers. Int J Mol Sci. 2020;21:8535.","journal-title":"Int J Mol Sci"},{"key":"2830_CR22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s13311-022-01182-2","volume":"19","author":"MF Palmas","year":"2022","unstructured":"Palmas MF, Ena A, Burgaletto C, Casu MA, Cantarella G, Carboni E, et al. Repurposing pomalidomide as a neuroprotective drug: efficacy in an alpha-synuclein-based model of Parkinson\u2019s disease. Neurotherapeutics. 2022;19:305\u201324.","journal-title":"Neurotherapeutics"},{"key":"2830_CR23","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.3390\/cells11172628","volume":"11","author":"MF Palmas","year":"2022","unstructured":"Palmas MF, Etzi M, Pisanu A, Camoglio C, Sagheddu C, Santoni M, et al. The intranigral infusion of human-alpha synuclein oligomers induces a cognitive impairment in rats associated with changes in neuronal firing and neuroinflammation in the anterior cingulate cortex. Cells. 2022;11:2628.","journal-title":"Cells"},{"key":"2830_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 2023;14:176.","journal-title":"Cell Death Dis"},{"key":"2830_CR25","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/ng.642","volume":"42","author":"TH Hamza","year":"2010","unstructured":"Hamza TH, Zabetian CP, Tenesa A, Laederach A, Montimurro J, Yearout D, et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson\u2019s disease. Nat Genet. 2010;42:781\u20135.","journal-title":"Nat Genet"},{"key":"2830_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40035-024-00401-4","volume":"13","author":"E Leandrou","year":"2024","unstructured":"Leandrou E, Chalatsa I, Anagnostou D, Machalia C, Semitekolou M, Filippa V, et al. \u03b1-Synuclein oligomers potentiate neuroinflammatory NF-\u03baB activity and induce Cav3.2 calcium signaling in astrocytes. Transl Neurodegener. 2024;13:11.","journal-title":"Transl Neurodegener"},{"key":"2830_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/ana.25557","volume":"86","author":"V Grozdanov","year":"2019","unstructured":"Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, et al. Increased immune activation by pathologic \u03b1-synuclein in Parkinson\u2019s disease. Ann Neurol. 2019;86:593\u2013606.","journal-title":"Ann Neurol"},{"key":"2830_CR28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/jnc.14710","volume":"150","author":"LP Diniz","year":"2019","unstructured":"Diniz LP, Matias I, Araujo APB, Garcia MN, Barros-Arag\u00e3o FGQ, Alves-Leon SV, et al. \u03b1-synuclein oligomers enhance astrocyte-induced synapse formation through TGF-\u03b21 signaling in a Parkinson\u2019s disease model. J Neurochem. 2019;150:138\u201357.","journal-title":"J Neurochem"},{"key":"2830_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fncel.2018.00247","volume":"12","author":"SA Ferreira","year":"2018","unstructured":"Ferreira SA, Romero-Ramos M. Microglia Response During Parkinson\u2019s Disease: Alpha-Synuclein Intervention. Front Cell Neurosci. 2018;12:247.","journal-title":"Front Cell Neurosci"},{"key":"2830_CR30","doi-asserted-by":"publisher","first-page":"5916","DOI":"10.1007\/s00415-024-12554-3","volume":"271","author":"AF Vega-Benedetti","year":"2024","unstructured":"Vega-Benedetti AF, Porcedda C, Ercoli T, Fusco G, Burgaletto C, Pillai R, et al. Immune responses to oligomeric \u03b1-synuclein in Parkinson\u2019s disease peripheral blood mononuclear cells. J Neurol. 2024;271:5916\u201329.","journal-title":"J Neurol"},{"key":"2830_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.639646","volume":"15","author":"F Piancone","year":"2021","unstructured":"Piancone F, Saresella M, La Rosa F, Marventano I, Meloni M, Navarro J, et al. Inflammatory responses to monomeric and aggregated \u03b1-synuclein in peripheral blood of Parkinson disease patients. Front Neurosci. 2021;15:639646.","journal-title":"Front Neurosci"},{"key":"2830_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.726476","volume":"15","author":"L Veys","year":"2021","unstructured":"Veys L, Devroye J, Lefevere E, Cools L, Vandenabeele M, De Groef L. Characterizing the retinal phenotype of the Thy1-h[A30P]\u03b1-syn mouse model of Parkinson\u2019s disease. Front Neurosci. 2021;15:726476.","journal-title":"Front Neurosci"},{"key":"2830_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109617119","volume":"119","author":"SS Ghanem","year":"2022","unstructured":"Ghanem SS, Majbour NK, Vaikath NN, Ardah MT, Erskine D, Jensen NM, et al. \u03b1-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity. Proc Natl Acad Sci USA. 2022;119:e2109617119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2830_CR34","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40478-023-01575-0","volume":"11","author":"D P\u00e9rez-Acu\u00f1a","year":"2023","unstructured":"P\u00e9rez-Acu\u00f1a D, Rhee KH, Shin SJ, Ahn J, Lee J-Y, Lee S-J. Retina-to-brain spreading of \u03b1-synuclein after intravitreal injection of preformed fibrils. Acta Neuropathol Commun. 2023;11:83.","journal-title":"Acta Neuropathol Commun"},{"key":"2830_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27657-y","volume":"13","author":"MT Bueno-Carrasco","year":"2022","unstructured":"Bueno-Carrasco MT, Cu\u00e9llar J, Flydal MI, Santiago C, Kr\u00e5kenes T-A, Kleppe R, et al. Structural mechanism for tyrosine hydroxylase inhibition by dopamine and reactivation by Ser40 phosphorylation. Nat Commun. 2022;13:74.","journal-title":"Nat Commun"},{"key":"2830_CR36","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2023.19","volume":"25","author":"H Wang","year":"2023","unstructured":"Wang H. microRNA pathological mechanisms between Parkinson\u2019s disease, Alzheimer\u2019s disease, glaucoma and macular degeneration. Expert Rev Mol Med. 2023;25:e24.","journal-title":"Expert Rev Mol Med"},{"key":"2830_CR37","doi-asserted-by":"crossref","unstructured":"Tao H, Liu Y, Hou Y. miRNA\u2011384\u20115p regulates the progression of Parkinson\u2019s disease by targeting SIRT1 in mice and SH\u2011SY5Y cell. Int J Mol Med [Internet]. 2019 [cited 2024 Jul 31]; Available from: http:\/\/www.spandidos-publications.com\/10.3892\/ijmm.2019.4426.","DOI":"10.3892\/ijmm.2019.4426"},{"key":"2830_CR38","doi-asserted-by":"publisher","first-page":"C755","DOI":"10.1152\/ajpcell.00226.2015","volume":"310","author":"M Jiang","year":"2016","unstructured":"Jiang M, Yun Q, Shi F, Niu G, Gao Y, Xie S, et al. Downregulation of miR-384-5p attenuates rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through inhibiting endoplasmic reticulum stress. Am J Physiol -Cell Physiol. 2016;310:C755\u201363.","journal-title":"Am J Physiol -Cell Physiol"},{"key":"2830_CR39","doi-asserted-by":"publisher","first-page":"D239","DOI":"10.1093\/nar\/gkx1141","volume":"46","author":"D Karagkouni","year":"2018","unstructured":"Karagkouni D, Paraskevopoulou MD, Chatzopoulos S, Vlachos IS, Tastsoglou S, Kanellos I, et al. DIANA-TarBase v8: a decade-long collection of experimentally supported miRNA-gene interactions. Nucleic Acids Res. 2018;46:D239\u201345.","journal-title":"Nucleic Acids Res"},{"key":"2830_CR40","first-page":"103","volume":"2","author":"M Reczko","year":"2011","unstructured":"Reczko M, Maragkakis M, Alexiou P, Papadopoulos GL, Hatzigeorgiou AG. Accurate microRNA target prediction using detailed binding site accessibility and machine learning on proteomics data. Front Genet. 2011;2:103.","journal-title":"Front Genet"},{"key":"2830_CR41","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1126\/science.aan6160","volume":"358","author":"G Fusco","year":"2017","unstructured":"Fusco G, Chen SW, Williamson PTF, Cascella R, Perni M, Jarvis JA, et al. Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Science. 2017;358:1440\u20133.","journal-title":"Science"},{"key":"2830_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2023.114651","volume":"372","author":"MF Manchinu","year":"2024","unstructured":"Manchinu MF, Pala M, Palmas MF, Diana MA, Maschio A, Etzi M, et al. Region-specific changes in gene expression are associated with cognitive deficits in the alpha-synuclein-induced model of Parkinson\u2019s disease: a transcriptomic profiling study. Exp Neurol. 2024;372:114651.","journal-title":"Exp Neurol"},{"key":"2830_CR43","doi-asserted-by":"publisher","first-page":"115338","DOI":"10.1016\/j.biopha.2023.115338","volume":"166","author":"J Wei","year":"2023","unstructured":"Wei J, Zhang Y, Li H, Wang F, Yao S. Toll-like receptor 4: a potential therapeutic target for multiple human diseases. Biomed Pharmacother. 2023;166:115338.","journal-title":"Biomed Pharmacother"},{"key":"2830_CR44","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/mds.27914","volume":"35","author":"J Lee","year":"2020","unstructured":"Lee J, Ahn J, Oh S, Shin JY, Kim YK, Nam H, et al. Retina thickness as a marker of neurodegeneration in prodromal lewy body disease. Mov Disord. 2020;35:349\u201354.","journal-title":"Mov Disord"},{"key":"2830_CR45","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s00018-022-04240-2","volume":"79","author":"GK Tofaris","year":"2022","unstructured":"Tofaris GK. Initiation and progression of \u03b1-synuclein pathology in Parkinson\u2019s disease. Cell Mol Life Sci. 2022;79:210.","journal-title":"Cell Mol Life Sci"},{"key":"2830_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2018.09.013","volume":"121","author":"N Mammadova","year":"2019","unstructured":"Mammadova N, Summers CM, Kokemuller RD, He Q, Ding S, Baron T, et al. Accelerated accumulation of retinal \u03b1-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson\u2019s disease. Neurobiol Dis. 2019;121:1\u201316.","journal-title":"Neurobiol Dis"},{"key":"2830_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40478-016-0346-z","volume":"4","author":"EM Normando","year":"2016","unstructured":"Normando EM, Davis BM, De Groef L, Nizari S, Turner LA, Ravindran N, et al. The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson\u2019s disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain. Acta Neuropathol Commun. 2016;4:86.","journal-title":"Acta Neuropathol Commun"},{"key":"2830_CR48","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.bbr.2017.10.021","volume":"352","author":"S Vingill","year":"2018","unstructured":"Vingill S, Connor-Robson N, Wade-Martins R. Are rodent models of Parkinson\u2019s disease behaving as they should?. Behav Brain Res. 2018;352:133\u201341.","journal-title":"Behav Brain Res"},{"key":"2830_CR49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ajpath.2024.01.017","volume":"194","author":"T Xu","year":"2024","unstructured":"Xu T, Liu X, Lin X, Xiao J, Zhang D, Ye F, et al. Abnormal \u03b1-synuclein aggregates cause synaptic- and microcircuit-specific deficits in the retinal rod pathway. Am J Pathol. 2024;194:796\u2013809.","journal-title":"Am J Pathol"},{"key":"2830_CR50","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/01677063.2017.1395876","volume":"31","author":"J Letelier","year":"2017","unstructured":"Letelier J, Bovolenta P, Mart\u00ednez-Morales JR. The pigmented epithelium, a bright partner against photoreceptor degeneration. J Neurogenet. 2017;31:203\u201315.","journal-title":"J Neurogenet"},{"key":"2830_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.3390\/biom10060945","volume":"10","author":"SR Oliveira","year":"2020","unstructured":"Oliveira SR, Dion\u00edsio PA, Correia Guedes L, Gon\u00e7alves N, Coelho M, Rosa MM, et al. Circulating inflammatory miRNAs associated with Parkinson\u2019s disease pathophysiology. Biomolecules. 2020;10:945.","journal-title":"Biomolecules"},{"key":"2830_CR52","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s43587-021-00046-2","volume":"1","author":"LS Rosenthal","year":"2021","unstructured":"Rosenthal LS, Yang J, Mao X. Dysregulated miRNAs mark Parkinson\u2019s disease progression. Nat Aging. 2021;1:241\u20132.","journal-title":"Nat Aging"},{"key":"2830_CR53","doi-asserted-by":"publisher","first-page":"e25443","DOI":"10.1371\/journal.pone.0025443","volume":"6","author":"M Martins","year":"2011","unstructured":"Martins M, Rosa A, Guedes LC, Fonseca BV, Gotovac K, Violante S, et al. Convergence of miRNA expression profiling, \u03b1-synuclein interacton and GWAS in Parkinson\u2019s disease. PLoS ONE. 2011;6:e25443.","journal-title":"PLoS ONE"},{"key":"2830_CR54","doi-asserted-by":"publisher","first-page":"1012.e11","DOI":"10.1016\/j.neurobiolaging.2011.10.030","volume":"33","author":"JD Mills","year":"2012","unstructured":"Mills JD, Janitz M. Alternative splicing of mRNA in the molecular pathology of neurodegenerative diseases. Neurobiol Aging. 2012;33:1012.e11\u20131012.e24.","journal-title":"Neurobiol Aging"},{"key":"2830_CR55","doi-asserted-by":"publisher","first-page":"e0240855","DOI":"10.1371\/journal.pone.0240855","volume":"15","author":"S Fazeli","year":"2020","unstructured":"Fazeli S, Motovali-Bashi M, Peymani M, Hashemi M-S, Etemadifar M, Nasr-Esfahani MH, et al. A compound downregulation of SRRM2 and miR-27a-3p with upregulation of miR-27b-3p in PBMCs of Parkinson\u2019s patients is associated with the early stage onset of disease. PLoS ONE. 2020;15:e0240855.","journal-title":"PLoS ONE"},{"key":"2830_CR56","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3233\/JAD-2008-14103","volume":"14","author":"JP Cogswell","year":"2008","unstructured":"Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, et al. Identification of miRNA changes in Alzheimer\u2019s disease brain and CSF yields putative biomarkers and insights into disease pathways. JAD. 2008;14:27\u201341.","journal-title":"JAD"},{"key":"2830_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2024.102141","volume":"35","author":"K Kiel","year":"2024","unstructured":"Kiel K, Kr\u00f3l SK, Bronisz A, Godlewski J. MiR-128-3p\u2014a gray eminence of the human central nervous system. Mol Ther Nucleic Acids. 2024;35:102141.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2830_CR58","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1874467215666220510112118","volume":"16","author":"Y Kartal","year":"2023","unstructured":"Kartal Y, Tokat UM, Kelicen-Ugur P, Y\u0131lmaz S, Karahan S, Budak MT. Evaluation of the relationship between aromatase\/sirtuin1 interaction and miRNA expression in human neuroblastoma cells. Curr Mol Pharm. 2023;16:609\u201328.","journal-title":"Curr Mol Pharm"},{"key":"2830_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/6782872","volume":"2020","author":"F Jiao","year":"2020","unstructured":"Jiao F, Gong Z. The beneficial roles of SIRT1 in neuroinflammation-related diseases. Oxid Med Cell Longev. 2020;2020:1\u201319.","journal-title":"Oxid Med Cell Longev"},{"key":"2830_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172847","volume":"867","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Anoopkumar-Dukie S, Arora D, Davey AK. Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases. Eur J Pharm. 2020;867:172847.","journal-title":"Eur J Pharm"},{"key":"2830_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.brainresbull.2022.04.012","volume":"185","author":"X Chen","year":"2022","unstructured":"Chen X, Wei G, Li D, Fan Y, Zeng Y, Qian Z, et al. Sirtuin 1 alleviates microglia-induced inflammation by modulating the PGC-1\u03b1\/Nrf2 pathway after traumatic brain injury in male rats. Brain Res Bull. 2022;185:28\u201338.","journal-title":"Brain Res Bull"},{"key":"2830_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.770744","volume":"12","author":"D-Y Xia","year":"2021","unstructured":"Xia D-Y, Yuan J-L, Jiang X-C, Qi M, Lai N-S, Wu L-Y, et al. SIRT1 promotes M2 microglia polarization via reducing ROS-mediated NLRP3 inflammasome signaling after subarachnoid hemorrhage. Front Immunol. 2021;12:770744.","journal-title":"Front Immunol"},{"key":"2830_CR63","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.3390\/ijms22073396","volume":"22","author":"K Makabe","year":"2021","unstructured":"Makabe K, Sugita S, Futatsugi Y, Takahashi M. Dynamics of cyclooxygenase-1 positive microglia\/macrophage in the retina of pathological model mice as a biomarker of the retinal inflammatory diseases. Int J Mol Sci. 2021;22:3396.","journal-title":"Int J Mol Sci"},{"key":"2830_CR64","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bbi.2019.06.042","volume":"81","author":"A Kouli","year":"2019","unstructured":"Kouli A, Horne CB, Williams-Gray CH. Toll-like receptors and their therapeutic potential in Parkinson\u2019s disease and \u03b1-synucleinopathies. Brain Behav Immun. 2019;81:41\u201351.","journal-title":"Brain Behav Immun"},{"key":"2830_CR65","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/glia.22437","volume":"61","author":"L Fellner","year":"2013","unstructured":"Fellner L, Irschick R, Schanda K, Reindl M, Klimaschewski L, Poewe W, et al. Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349\u201360.","journal-title":"Glia"},{"key":"2830_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-015-0192-0","volume":"16","author":"EH Rannikko","year":"2015","unstructured":"Rannikko EH, Weber SS, Kahle PJ. Exogenous \u03b1-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes. BMC Neurosci. 2015;16:57.","journal-title":"BMC Neurosci"},{"key":"2830_CR67","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248\u201354.","journal-title":"Anal Biochem"},{"key":"2830_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04165-x","volume":"12","author":"C Burgaletto","year":"2021","unstructured":"Burgaletto C, Platania CBM, Di Benedetto G, Munaf\u00f2 A, Giurdanella G, Federico C, et al. Targeting the miRNA-155\/TNFSF10 network restrains inflammatory response in the retina in a mouse model of Alzheimer\u2019s disease. Cell Death Dis. 2021;12:905.","journal-title":"Cell Death Dis"},{"key":"2830_CR69","volume":"25","author":"MH Shihan","year":"2021","unstructured":"Shihan MH, Novo SG, Le Marchand SJ, Wang Y, Duncan MK. A simple method for quantitating confocal fluorescent images. Biochem Biophys Rep. 2021;25:100916.","journal-title":"Biochem Biophys Rep"},{"key":"2830_CR70","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1111\/bph.14214","volume":"175","author":"D Lecca","year":"2018","unstructured":"Lecca D, Janda E, Mulas G, Diana A, Martino C, Angius F, et al. Boosting phagocytosis and anti-inflammatory phenotype in microglia mediates neuroprotection by PPAR\u03b3 agonist MDG548 in Parkinson\u2019s disease models. Br J Pharm. 2018;175:3298\u2013314.","journal-title":"Br J Pharm"},{"key":"2830_CR71","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1365-2818.2002.01006.x","volume":"206","author":"PR Mouton","year":"2002","unstructured":"Mouton PR, Gokhale AM, Ward NL, West MJ. Stereological length estimation using spherical probes. J Microsc. 2002;206:54\u201364.","journal-title":"J Microsc"},{"key":"2830_CR72","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175\u201391.","journal-title":"Behav Res Methods"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02830-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02830-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02830-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:02:50Z","timestamp":1764345770000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02830-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":72,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2830"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02830-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"We did not use human samples in this study. Animal experiments were performed in accordance with the ARRIVE guidelines and with the guidelines and protocols approved by the European Community (2010\/63UE L 276 20\/10\/2010), and the Italian law (D.Lgs. 26\/2014). Experimental protocols were approved by the Italian Ministry of Health (authorization N. 766\/2020-PR).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"550"}}